AR105193A1 - Síntesis de shishijimicina a y sus análogos - Google Patents

Síntesis de shishijimicina a y sus análogos

Info

Publication number
AR105193A1
AR105193A1 ARP160101973A ARP160101973A AR105193A1 AR 105193 A1 AR105193 A1 AR 105193A1 AR P160101973 A ARP160101973 A AR P160101973A AR P160101973 A ARP160101973 A AR P160101973A AR 105193 A1 AR105193 A1 AR 105193A1
Authority
AR
Argentina
Prior art keywords
substituted
hydrogen
alkyl
alkoxy
groups
Prior art date
Application number
ARP160101973A
Other languages
English (en)
Spanish (es)
Inventor
Wood James
Sohn Te
Ik - Lu Zhaoyong
Li Roufan
C Nicolaou Kyriacos
Original Assignee
Univ Rice William M
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rice William M filed Critical Univ Rice William M
Publication of AR105193A1 publication Critical patent/AR105193A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP160101973A 2015-06-29 2016-06-29 Síntesis de shishijimicina a y sus análogos AR105193A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562186191P 2015-06-29 2015-06-29

Publications (1)

Publication Number Publication Date
AR105193A1 true AR105193A1 (es) 2017-09-13

Family

ID=57609044

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101973A AR105193A1 (es) 2015-06-29 2016-06-29 Síntesis de shishijimicina a y sus análogos

Country Status (19)

Country Link
US (1) US10590158B2 (enExample)
EP (1) EP3313389A1 (enExample)
JP (1) JP2018525346A (enExample)
KR (1) KR20180053294A (enExample)
CN (1) CN108348489A (enExample)
AR (1) AR105193A1 (enExample)
AU (1) AU2016286071A1 (enExample)
BR (1) BR112017028557A2 (enExample)
CA (1) CA2990206A1 (enExample)
CL (1) CL2017003500A1 (enExample)
HK (1) HK1254923A1 (enExample)
IL (1) IL256345A (enExample)
MA (1) MA42273A (enExample)
MX (1) MX2017016885A (enExample)
PE (1) PE20180658A1 (enExample)
PH (1) PH12018500014A1 (enExample)
RU (1) RU2018102808A (enExample)
TW (1) TW201713634A (enExample)
WO (1) WO2017004172A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110357785B (zh) * 2019-07-26 2020-03-24 东莞市领创环保材料科技有限公司 一种氰酸酯树脂增塑剂的制备方法
CN115197188B (zh) * 2021-04-12 2023-12-26 南开大学 一类具有五环骨架的倍半萜氢醌化合物及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264586A (en) * 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5261586A (en) * 1992-03-26 1993-11-16 Chen Jen Fu Yarn feeding device with a guiding flange
US5550246A (en) 1994-09-07 1996-08-27 The Scripps Research Institute Calicheamicin mimics
JP2003238584A (ja) * 2002-02-08 2003-08-27 Yamanouchi Pharmaceut Co Ltd 新規エンジイン化合物
TW200539855A (en) * 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
US10131682B2 (en) * 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules

Also Published As

Publication number Publication date
PH12018500014A1 (en) 2018-07-09
WO2017004172A1 (en) 2017-01-05
IL256345A (en) 2018-02-28
MA42273A (fr) 2018-05-02
US10590158B2 (en) 2020-03-17
CL2017003500A1 (es) 2018-04-27
AU2016286071A8 (en) 2019-08-08
AU2016286071A1 (en) 2018-02-01
CN108348489A (zh) 2018-07-31
BR112017028557A2 (pt) 2018-09-04
RU2018102808A (ru) 2019-07-30
MX2017016885A (es) 2018-09-06
EP3313389A1 (en) 2018-05-02
US20180327439A1 (en) 2018-11-15
PE20180658A1 (es) 2018-04-17
JP2018525346A (ja) 2018-09-06
HK1254923A1 (zh) 2019-08-02
CA2990206A1 (en) 2017-01-05
TW201713634A (zh) 2017-04-16
WO2017004172A8 (en) 2018-01-11
KR20180053294A (ko) 2018-05-21
RU2018102808A3 (enExample) 2020-04-30

Similar Documents

Publication Publication Date Title
AR125754A1 (es) Compuestos anticancerígenos dirigidos a los receptores de hormonas nucleares
AR091424A1 (es) Compuestos triciclicos sustituidos como inhibidores de receptores del factor de crecimiento del fibroplasto (fgfr)
AR129299A1 (es) Compuestos para modular complejos de factores asociados a brg1 o brm (baf)
AR106301A1 (es) Composiciones de pirrolpirimidina como inhibidores de quinasas
AR096643A1 (es) Procedimiento de síntesis para la preparación de análogos macrocíclicos c1-ceto de halicondrina b e intermediarios útiles en la misma incluyendo intermediarios que contienen grupos -so₂-(p-tolilo)
AR087793A1 (es) Compuestos de benzofurano sustituido y metodos para el uso de los mismos en el tratamiento de enfermedades virales
AR087769A1 (es) Pirimidinas condensadas sustituidas y su uso como activadores de la guanilatociclasa soluble
AR087792A1 (es) Compuestos heterociclicos tetraciclicos y metodos para el uso de los mismos en el tratamiento de enfermedades virales
AR091279A1 (es) Inhibidores macrociclicos de virus flaviviridae
AR086008A1 (es) Compuestos de benceno sustituidos con arilo o heteroarilo
AR108011A1 (es) Moduladores receptores de estrógenos
AR109709A1 (es) Inhibidores de la fosfatidilinositol 3-quinasa
AR107321A1 (es) Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos
AR094557A1 (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn
AR087563A1 (es) Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv)
AR050536A1 (es) Derivados de pirimidina, procesos de preparacion y composiciones farmaceuticas que los comprenden
AR094550A1 (es) Inhibidores de btk
AR088474A1 (es) Derivados de alcoholes de 1-fenil-2-piridinilalquilo como inhibidores de la fosfodiesterasa
AR075235A1 (es) Derivados de indol como agentes anticancer.
AR103566A1 (es) Compuestos derivados de heteroarilo y heterociclo condensados
AR092347A1 (es) Derivados de azaindol
AR101317A1 (es) Moléculas que poseen ciertas utilidades plaguicidas, intermediarios, composiciones y procesos relacionados con dichas moléculas
AR090678A1 (es) Derivados de fenil-tetrahidroisoquinolina como inhibidores de la aldosterona-sintasa y un metodo para su sintesis
AR092491A1 (es) Derivados de imidazolin-5-ona utiles como inhibidores de fasn para el tratamiento contra el cancer
AR103192A1 (es) Isotiazolamidas, procesos para su preparación y su uso como herbicidas y/o reguladores del crecimiento vegetal

Legal Events

Date Code Title Description
FB Suspension of granting procedure